ERBB2 and pachyonychia congenita: In addition, a phase 1 clinical trial targeting HER2 demonstrated the clinical activity of HER2 CAR-T cells in eleven enrolled patients with advanced biliary tract cancers and PC (NCT01935843) (Fig. 3).